Breaking News, Collaborations & Alliances

Catalent and MigVax to Develop Oral COVID Vaccine

Sign agreement to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent, a contract development and manufacturing organization (CDMO) working with biopharma, cell, gene and consumer health partners, and MigVax, an Israeli biopharmaceutical company developing an oral subunit vaccine against COVID-19, have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine. MigVax’s lead oral vaccine program, MigVax-101, has shown positive results in preclinical tes...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters